Central nervous system (CNS) diseases – including Alzheimer’s disease, Parkinson’s disease, stroke, traumatic brain injury and multiple sclerosis – affect nearly 3 billion people worldwide, almost half of the global population. Over the past years, neuroinflammation has emerged as a common and critical driver of disease onset, progression and chronicity. But what fuels this inflammation? A growing body of evidence points to an upstream event: mitochondrial dysfunction within the cells of the neurovascular unit (NVU).
Mitochondrial control of neuroinflammation in CNS disease
Now, writing in Science Bulletin, Professor Kelong Ai and Professor Huang Qiong from Central South University (Changsha, China) present a comprehensive review that links mitochondrial damage in different NVU cell types to the vicious cycle of neuroinflammation, and propose a mechanism‑based classification of nanomedicines as a new treatment strategy. “Mitochondria are central to cellular metabolism, redox balance and inflammatory signaling,” explains Professor Ai. “In neurons, impaired energy supply, ROS bursts, calcium overload, defective quality control and disturbed mitochondrial trafficking all trigger neuroinflammation. In glia, mitochondrial dysfunction pushes microglia and astrocytes towards a pro‑inflammatory phenotype. In brain endothelial cells and pericytes, it disrupts the blood–brain barrier and allows peripheral immune cells to infiltrate.” This complex interplay forms a self‑amplifying loop that sustains neuroinflammation.
Mitochondrial dysfunction-targeted nanomedicines for regulating neuroinflammation in CNS diseases
However, delivering therapeutics to the CNS is notoriously difficult. The blood–brain barrier blocks more than 98% of small‑molecule drugs and virtually all macromolecules. Even if a drug reaches the brain, the double membrane of mitochondria presents a second formidable barrier. Conventional drugs also lack mitochondrial specificity, causing off‑target effects. Nanomedicine offers a way out. The review describes how intelligent nanomaterials can be designed to cross the blood–brain barrier, home to damaged mitochondria and restore their function. Importantly, the authors categorize existing nanomedicines according to the specific pathological mechanism they target: scavenging mitochondrial ROS, regulating calcium homeostasis and mPTP, repairing mitochondrial quality control (autophagy / biogenesis), and assisting mitochondrial transfer. In preclinical models, these nanomedicines have shown striking efficacy, reducing neuronal damage, inhibiting glial activation, preventing inflammatory storms and protecting blood–brain barrier integrity.
Challenges and Future Directions for Clinical Translation
Despite this promise, the road to clinical translation remains challenging. The review highlights several major hurdles: the “double‑edged sword” safety risk of interfering with healthy mitochondria, incomplete understanding of disease‑stage‑dependent mitochondrial dynamics, technical bottlenecks in Good Manufacturing Practice (GMP)‑compliant large‑scale production, and, perhaps most fundamental, a “Tower of Babel” in nanomedicine, i.e., the lack of standardized frameworks for evaluating and comparing different studies. To overcome these obstacles, the authors call for multi‑center, large‑scale preclinical and clinical studies to validate long‑term safety and efficacy. They advocate the establishment of standardized characterization and evaluation protocols, clear regulatory pathways, and the integration of mechanism‑based nanomedicine classifications into clinical trial design.
Science Bulletin
Literature review